Shire, Chronos Therapeutics deal

Chronos acquired three undisclosed preclinical development programs from Shire focused on fatigue in multiple sclerosis, addictive behaviors and post-traumatic stress disorder. Shire received equity in Chronos and is eligible for regulatory and sales milestones, plus royalties. Chronos will have worldwide development and marketing rights. ...